Molecular Partners (NASDAQ:MOLN – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Molecular Partners to similar businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.
Volatility and Risk
Molecular Partners has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Molecular Partners’ peers have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Molecular Partners and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Molecular Partners | 1 | 1 | 2 | 0 | 2.25 |
| Molecular Partners Competitors | 9838 | 15122 | 45436 | 1587 | 2.54 |
Molecular Partners presently has a consensus price target of $8.38, suggesting a potential upside of 160.90%. As a group, “Biotechnology” companies have a potential upside of 102.61%. Given Molecular Partners’ higher probable upside, equities research analysts plainly believe Molecular Partners is more favorable than its peers.
Profitability
This table compares Molecular Partners and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Molecular Partners | N/A | -80.03% | -62.56% |
| Molecular Partners Competitors | -12,357.18% | -197.96% | -30.56% |
Insider and Institutional Ownership
26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Molecular Partners and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Molecular Partners | $5.65 million | -$74.41 million | -1.91 |
| Molecular Partners Competitors | $728.25 million | $12.25 million | -15.19 |
Molecular Partners’ peers have higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Molecular Partners peers beat Molecular Partners on 8 of the 13 factors compared.
Molecular Partners Company Profile
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
